ANI Pharmaceuticals (BSFA) Stock Forecast & Price Target
BSFA Analyst Ratings
Strong Buy
6Buy2Hold0Sell
Based on 8 analysts giving stock ratings to ANI Pharmaceuticals in the past 3 months
BSFA Stock 12 Month Forecast
Average Price Target
EUR 95.73▲(48.42% Upside)Based on 8 Wall Street analysts offering 12 month price targets for ANI Pharmaceuticals in the last 3 months. The average price target is EUR 95.73 with a high forecast of EUR 108.51 and a low forecast of EUR 76.23. The average price target represents a 48.42% change from the last price of EUR 64.50.
Past 12 Months12 Month ForecastDec2025Sep2026
HighEUR 108.51
AverageEUR 95.73
LowEUR 76.23
Highest Price TargetHighestEUR 108.51Average Price TargetEUR 95.73Lowest Price TargetLowestEUR 76.23
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ekaterina Knyazkova | J.P. Morgan | EUR 103.13 | buy | 59.89%Upside | Reiterated | 10/22/26 | ||
| Vamil Divan | Guggenheim | EUR 106.72 | buy | 65.45%Upside | Reiterated | 10/05/26 | ||
| Les Sulewski | Oppenheimer | EUR 76.23 | hold | 18.18%Upside | Initiated | 09/23/26 | ||
| Brandon Folkes | H.C. Wainwright | EUR 108.51 | buy | 68.23%Upside | Reiterated | 09/21/26 | ||
| Daniel Clark | Leerink Partners | EUR 93.26 | buy | 44.60%Upside | Initiated | 09/09/26 | ||
| Glen Santangelo | Barclays | EUR 89.68 | buy | 39.03%Upside | Reiterated | 08/25/26 | ||
| Gary Nachman | Canaccord Genuity | EUR 81.61→EUR 80.71 | hold | 25.13%Upside | Reiterated | 08/10/26 | ||
 Unknown AnalystNot Ranked | Jefferies | EUR 107.61 | buy | 66.84%Upside | Reiterated | 08/10/26 | ||
| David Amsellem | Piper Sandler | EUR 99.54 | buy | 54.33%Upside | Reiterated | 04/23/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ekaterina Knyazkova | 10/22/26 | EUR 103.13 | buy | 59.89%Upside | Reiterated | J.P. Morgan | ||
| Vamil Divan | 10/05/26 | EUR 106.72 | buy | 65.45%Upside | Reiterated | Guggenheim | ||
| Les Sulewski | 09/23/26 | EUR 76.23 | hold | 18.18%Upside | Initiated | Oppenheimer | ||
| Brandon Folkes | 09/21/26 | EUR 108.51 | buy | 68.23%Upside | Reiterated | H.C. Wainwright | ||
| Daniel Clark | 09/09/26 | EUR 93.26 | buy | 44.60%Upside | Initiated | Leerink Partners | ||
| Glen Santangelo | 08/25/26 | EUR 89.68 | buy | 39.03%Upside | Reiterated | Barclays | ||
| Gary Nachman | 08/10/26 | EUR 81.61→EUR 80.71 | hold | 25.13%Upside | Reiterated | Canaccord Genuity | ||
| Unknown AnalystNot Ranked | 08/10/26 | EUR 107.61 | buy | 66.84%Upside | Reiterated | Jefferies | ||
| David Amsellem | 04/23/26 | EUR 99.54 | buy | 54.33%Upside | Reiterated | Piper Sandler |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering ANI Pharmaceuticals
3 Months
Success Rate7/9 ratings generated profit
78%
Average Return
+15.36%
Copying Faisal Khurshid's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +15.36% per trade.
1 Year
Success Rate7/9 ratings generated profit
78%
Average Return
+19.57%
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +19.57% per trade.
2 Years
Success Rate7/9 ratings generated profit
78%
Average Return
+9.09%
Copying Faisal Khurshid's trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +9.09% per trade.
BSFA Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 5 | 6 | 7 |
| Buy | 4 | 5 | 4 | 5 | 3 |
| Hold | 1 | 2 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 7 | 9 | 11 | 14 | 12 |
In the current month, BSFA has received 10 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BSFA average Analyst price target in the past 3 months is 95.73.
BSFA Financial Forecast
HighEUR 2.08
ConsensusEUR 1.95
LowEUR 1.81
BSFA Earnings Forecast
Next quarter’s earnings estimate for BSFA is EUR 1.95 with a range of EUR 1.81 to EUR 2.08. The previous quarter’s EPS was EUR 1.98. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 256M
ConsensusEUR 251M
LowEUR 244M
BSFA Sales Forecast
Next quarter’s sales forecast for BSFA is EUR 250.59M with a range of EUR 244.36M to EUR 255.99M. The previous quarter’s sales results were EUR 237.87M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
BSFA Stock Forecast FAQ
What is DE:BSFA’s average 12-month price target, according to analysts?
Based on analyst ratings, ANI Pharmaceuticals’s 12-month average price target is €95.73.
What is DE:BSFA’s upside potential, based on the analysts’ average price target?
ANI Pharmaceuticals has 48.42% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ANI Pharmaceuticals a Buy, Sell or Hold?
ANI Pharmaceuticals has a consensus rating of Strong Buy, which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
What is ANI Pharmaceuticals’s share price target?
The average share price target for ANI Pharmaceuticals is €95.73. This is based on 8 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €108.51, and the lowest forecast is €76.23. The average share price target represents a 48.42% increase from the current price of €64.5.
What do analysts say about ANI Pharmaceuticals?
ANI Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of ANI Pharmaceuticals?
To buy shares of DE:BSFA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
